24/7 Wall Street
30 Sept 2026, 15:48 UTC · 1h ago
Verdict
Headline leans bearish. We score QURE −0.80 across four claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.80strongly bearish
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
uniQure's AMT-130 high-dose group showed a 44% slowing of disease decline at 48 months, down from approximately 75% at 36 months.
Priced inanalysis of data that caused stock to crash 37%
So whatThe lack of statistical significance and 53% missing data increase the risk of a negative FDA advisory committee review.
More negative than 99% of claims this week
Continue reading
5 related stories
More negative than 84% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
The company expects FDA acceptance of its Huntington's application in Q4 2026, with a decision roughly eight months later.
Priced inno timing evidence
So whatA decision in mid-2027 creates a binary catalyst that determines if the current $24.51 price is a floor or a cliff.
More positive than 80% of claims this week
uniQure holds $810.3 million in cash and investments to fund operations into 2030.
Priced inno timing evidence
So whatWith TTM diluted EPS at -$4.16, this liquidity runway eliminates the need for dilutive financing before the 2027 FDA decision.
More positive than 67% of claims this week
uniQure paused higher doses in its Fabry program due to Grade 3 liver-enzyme elevations and discontinued its ALS program.
Priced inno timing evidence
So whatThese pipeline failures concentrate 100% of the company's valuation risk onto the single AMT-130 Huntington's asset.
More negative than 76% of claims this week
Which stocks this story touches
More negative than 84% of ticker scores this week
Stock crashed over 37% following data showing a decline in efficacy for its Huntington's disease therapy and a lack of statistical significance in four-year results.
More positive than 68% of ticker scores this week
Mentioned as a better investment choice due to strong year-to-date performance and diversified exposure that mitigates single-stock binary risk.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
CNBC
7h ago
+0.7%
Price is moving against the score
$24.69 vs $24.51 close before publication (Sep 29) · not market-adjusted
QURE chart →
